Staging of Invasive Ductal Carcinoma

Initial Clinical Evaluation

The American College of Radiology recommends a thorough clinical and imaging evaluation, including physical examination, bilateral mammography, and pathologic assessment with hormone receptor and HER2 status determination, for invasive ductal carcinoma staging 1, 2
The initial clinical evaluation must assess specific clinical parameters, including tumor characteristics, such as size, location, and relationship to the nipple-areolar complex, and axillary examination for palpable lymphadenopathy status 1
The National Comprehensive Cancer Network recommends a contralateral breast assessment to identify synchronous disease and an evaluation of systemic symptoms to detect metastatic disease 1, 3

Bilateral mammography is required within 3 months to establish the extent of disease and rule out multicentric involvement, as recommended by the American College of Radiology 1
Breast ultrasound is performed as clinically warranted to characterize lesions, according to the National Comprehensive Cancer Network 3
Chest imaging is required for stage III disease, as recommended by the National Comprehensive Cancer Network 3

The American Society of Clinical Oncology recommends histologic confirmation with WHO classification, tumor grade, hormone receptor status, and HER2 status for every invasive ductal carcinoma 4, 5
Lymphovascular invasion is associated with increased recurrence risk, and surgical margin assessment requires proper specimen orientation, as recommended by the American College of Radiology 1, 4

The American College of Radiology recommends sentinel lymph node biopsy as the standard approach for axillary staging in invasive carcinoma, with the number of positive nodes significantly impacting prognosis and guiding adjuvant therapy decisions 1, 4

The National Comprehensive Cancer Network recommends required baseline studies, including complete blood count with platelets, liver function tests, and alkaline phosphatase, as well as a routine chemistry panel 3, 5

The American Joint Committee on Cancer recommends applying the TNM staging system, incorporating tumor size, nodal status, and metastatic disease, to determine the stage of invasive ductal carcinoma 4, 5

For stage I-II disease, the National Comprehensive Cancer Network recommends a streamlined staging evaluation, including history, physical examination, laboratory studies, bilateral mammography, and pathologic assessment, with additional imaging only indicated for symptoms or abnormal findings 2, 3
For stage III disease, more extensive staging includes all baseline studies, plus optional bone scan and abdominal imaging, with PET/CT reserved for equivocal findings, as recommended by the National Comprehensive Cancer Network 3

The American College of Radiology warns against over-imaging early-stage disease, which can lead to false positives, unnecessary biopsies, and patient anxiety 2
Inadequate preoperative imaging can result in incomplete tumor excision, and failure to obtain bilateral mammography can miss synchronous contralateral disease, as noted by the American College of Radiology 1